TG Ther­a­peu­tics shares rock­et up on suc­cess­ful PhI­II leukemia study, tee­ing up a shot at ac­cel­er­at­ed FDA OK

Shares of TG Ther­a­peu­tics $TGTX rock­et­ed up 64% this morn­ing af­ter the New York-based biotech re­port­ed that its lead can­cer drug scored a

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA